Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[⁶¹Cu]Cu-NODAGA-LM3
- Development stage
- Unknown
- Lead developer
- Nuclidium
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
[⁶¹Cu]Cu-NODAGA-LM3 (also known as 61Cu-TraceNET or 61Cu-NU201) is a novel copper-61-labeled somatostatin receptor subtype 2 (SSTR2) antagonist developed by Nuclidium in collaboration with the University of Basel. It is designed as a positron emission tomography (PET) imaging agent for the detection, staging, and management of SSTR2-positive tumors, including gastroenteropancreatic and bronchopulmonary neuroendocrine tumors (GEP-NETs and BP-NETs) as well as metastatic breast cancer. By utilizing cyclotron-produced copper-61, which has a 3.3-hour half-life, the tracer allows for delayed imaging and centralized distribution. It offers superior spatial resolution and count statistics compared to gallium-68-based agents, and demonstrates lower physiological background uptake in organs like the liver and spleen, thereby improving tumor-to-background contrast and lesion detection. It is developed as the diagnostic companion to the therapeutic agent 67Cu-TraceNET (67Cu-NODAGA-LM3) under Nuclidium's SSTR2-targeted theranostic program.
- Brand names
- 61Cu-TraceNETTraceNET
- Other names
- 61Cu-NODAGA-LM3Copper-61-NODAGA-LM3Copper61-NODAGA-LM3Copper 61-NODAGA-LM3Copper-61-tagged NODAGA-LM3Copper61-tagged NODAGA-LM3Copper 61-tagged NODAGA-LM3[61Cu]Cu-NODAGA-LM3
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on [⁶¹Cu]Cu-NODAGA-LM3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [⁶¹Cu]Cu-NODAGA-LM3.